丙戊酸钠治疗患者血清成纤维细胞生长因子-21水平与偏头痛严重程度的相关性

IF 0.5 Q4 CLINICAL NEUROLOGY
Hamed Cheraghmakani, Mehrdad Afzalinezhad, Monireh Ghazaeian, Parham Mortazavi, Narges Karimi, Sahar Fallah
{"title":"丙戊酸钠治疗患者血清成纤维细胞生长因子-21水平与偏头痛严重程度的相关性","authors":"Hamed Cheraghmakani, Mehrdad Afzalinezhad, Monireh Ghazaeian, Parham Mortazavi, Narges Karimi, Sahar Fallah","doi":"10.18502/cjn.v23i3.17600","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Mitochondrial metabolism disruption increases neuron excitability and reduces migraine attack threshold. This study investigates whether serum fibroblast growth factor-21 (FGF-21) levels in chronic migraine relate to headache severity and response to sodium valproate treatment. <b>Methods:</b> This pilot study involved 30 patients with chronic migraine treated with sodium valproate. Serum FGF-21 levels were assessed at baseline and after 12 weeks of treatment. Pain severity and disability were evaluated using visual analogue scale (VAS) and Migraine Disability Assessment (MIDAS). Paired t-test was used for the quantitative variables. The qualitative variables were evaluated using Pearson's chi-square test and Fisher's exact test. Moreover, correlation coefficients were calculated. A P < 0.05 was considered statistically significant. <b>Results:</b> Mean age of the patients was 42.9 ± 11.3 years. There was a significant reduction in headache severity between baseline and the end of the study regarding VAS scores (8.50 ± 1.50 vs. 5.30 ± 2.20, P < 0.001). The same reduction was observed in MIDAS during the study (61.20 ± 33.20 vs. 20.31 ± 17.07, P < 0.001). However, there was no significant changes in serum levels of FGF-21 over three months (299.53 ± 479.80 vs. 491.33 ± 456.64, P = 0.810), nor any relationship between these levels and headache severity scores (MIDAS: P = 0.658, VAS: P = 0.708). <b>Conclusion:</b> The results of this study did not show a significant correlation between FGF-21 serum levels and changes in VAS and MIDAS throughout the study. Further research on various mitochondrial pathways can provide valuable insights into the migraine pathophysiology and help identify more effective biomarkers for monitoring therapeutic regimens.</p>","PeriodicalId":40077,"journal":{"name":"Current Journal of Neurology","volume":"23 3","pages":"170-175"},"PeriodicalIF":0.5000,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994060/pdf/","citationCount":"0","resultStr":"{\"title\":\"Correlation between serum levels of fibroblast growth factor-21 and the severity of migraine headache in patients undergoing sodium valproate treatment.\",\"authors\":\"Hamed Cheraghmakani, Mehrdad Afzalinezhad, Monireh Ghazaeian, Parham Mortazavi, Narges Karimi, Sahar Fallah\",\"doi\":\"10.18502/cjn.v23i3.17600\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Mitochondrial metabolism disruption increases neuron excitability and reduces migraine attack threshold. This study investigates whether serum fibroblast growth factor-21 (FGF-21) levels in chronic migraine relate to headache severity and response to sodium valproate treatment. <b>Methods:</b> This pilot study involved 30 patients with chronic migraine treated with sodium valproate. Serum FGF-21 levels were assessed at baseline and after 12 weeks of treatment. Pain severity and disability were evaluated using visual analogue scale (VAS) and Migraine Disability Assessment (MIDAS). Paired t-test was used for the quantitative variables. The qualitative variables were evaluated using Pearson's chi-square test and Fisher's exact test. Moreover, correlation coefficients were calculated. A P < 0.05 was considered statistically significant. <b>Results:</b> Mean age of the patients was 42.9 ± 11.3 years. There was a significant reduction in headache severity between baseline and the end of the study regarding VAS scores (8.50 ± 1.50 vs. 5.30 ± 2.20, P < 0.001). The same reduction was observed in MIDAS during the study (61.20 ± 33.20 vs. 20.31 ± 17.07, P < 0.001). However, there was no significant changes in serum levels of FGF-21 over three months (299.53 ± 479.80 vs. 491.33 ± 456.64, P = 0.810), nor any relationship between these levels and headache severity scores (MIDAS: P = 0.658, VAS: P = 0.708). <b>Conclusion:</b> The results of this study did not show a significant correlation between FGF-21 serum levels and changes in VAS and MIDAS throughout the study. Further research on various mitochondrial pathways can provide valuable insights into the migraine pathophysiology and help identify more effective biomarkers for monitoring therapeutic regimens.</p>\",\"PeriodicalId\":40077,\"journal\":{\"name\":\"Current Journal of Neurology\",\"volume\":\"23 3\",\"pages\":\"170-175\"},\"PeriodicalIF\":0.5000,\"publicationDate\":\"2024-07-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11994060/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Journal of Neurology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/cjn.v23i3.17600\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Journal of Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/cjn.v23i3.17600","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:线粒体代谢紊乱增加神经元兴奋性,降低偏头痛发作阈值。本研究探讨慢性偏头痛患者血清成纤维细胞生长因子-21 (FGF-21)水平是否与头痛严重程度和丙戊酸钠治疗反应有关。方法:本初步研究纳入30例用丙戊酸钠治疗的慢性偏头痛患者。在基线和治疗12周后评估血清FGF-21水平。采用视觉模拟量表(VAS)和偏头痛残疾评估(MIDAS)对疼痛严重程度和残疾进行评估。定量变量采用配对t检验。采用Pearson卡方检验和Fisher精确检验对定性变量进行评估。并计算相关系数。P < 0.05为差异有统计学意义。结果:患者平均年龄42.9±11.3岁。在VAS评分方面,基线和研究结束时头痛严重程度显著降低(8.50±1.50比5.30±2.20,P < 0.001)。在研究期间,MIDAS患者也观察到相同的减少(61.20±33.20比20.31±17.07,P < 0.001)。然而,三个月内血清FGF-21水平无显著变化(299.53±479.80 vs 491.33±456.64,P = 0.810),这些水平与头痛严重程度评分之间也无任何关系(MIDAS: P = 0.658, VAS: P = 0.708)。结论:本研究结果未显示FGF-21血清水平与整个研究过程中VAS和MIDAS的变化有显著相关性。对各种线粒体途径的进一步研究可以为偏头痛的病理生理学提供有价值的见解,并有助于确定更有效的生物标志物来监测治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Correlation between serum levels of fibroblast growth factor-21 and the severity of migraine headache in patients undergoing sodium valproate treatment.

Background: Mitochondrial metabolism disruption increases neuron excitability and reduces migraine attack threshold. This study investigates whether serum fibroblast growth factor-21 (FGF-21) levels in chronic migraine relate to headache severity and response to sodium valproate treatment. Methods: This pilot study involved 30 patients with chronic migraine treated with sodium valproate. Serum FGF-21 levels were assessed at baseline and after 12 weeks of treatment. Pain severity and disability were evaluated using visual analogue scale (VAS) and Migraine Disability Assessment (MIDAS). Paired t-test was used for the quantitative variables. The qualitative variables were evaluated using Pearson's chi-square test and Fisher's exact test. Moreover, correlation coefficients were calculated. A P < 0.05 was considered statistically significant. Results: Mean age of the patients was 42.9 ± 11.3 years. There was a significant reduction in headache severity between baseline and the end of the study regarding VAS scores (8.50 ± 1.50 vs. 5.30 ± 2.20, P < 0.001). The same reduction was observed in MIDAS during the study (61.20 ± 33.20 vs. 20.31 ± 17.07, P < 0.001). However, there was no significant changes in serum levels of FGF-21 over three months (299.53 ± 479.80 vs. 491.33 ± 456.64, P = 0.810), nor any relationship between these levels and headache severity scores (MIDAS: P = 0.658, VAS: P = 0.708). Conclusion: The results of this study did not show a significant correlation between FGF-21 serum levels and changes in VAS and MIDAS throughout the study. Further research on various mitochondrial pathways can provide valuable insights into the migraine pathophysiology and help identify more effective biomarkers for monitoring therapeutic regimens.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current Journal of Neurology
Current Journal of Neurology CLINICAL NEUROLOGY-
CiteScore
0.80
自引率
14.30%
发文量
30
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信